Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Status:
Completed
Trial end date:
2016-06-23
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine the Maximum Tolerated Dose (MTD) of afatinib in
combination with 3-weekly trastuzumab in HER2 overexpressing cancer and to assess the
efficacy of afatinib given at the MTD dosage, with 3-weekly trastuzumab in HER2
overexpressing metastatic breast cancer.